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Background. Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) is the state-of-the-art diagnostic for nor-
ovirus. Cycle threshold (Ct), an indicator of viral load, may be associated with symptomatic disease as well as demographic and 
outbreak characteristics.
Methods. Data on (1) outbreak and sporadic cases and (2) asymptomatic controls in the United States and Latin America were 
analyzed. With multivariate regression models, we assessed relationships between various factors and Ct values, and we calculated 
odds ratios (ORs) for the presence of symptoms and attributable fractions of norovirus. Receiver-operating characteristic analysis 
was performed to define an optimal Ct cutoff to identify disease-causing infections.
Results. Cycle threshold values were lower (ie, higher viral loads) among symptomatic cases (model-adjusted mean ± standard 
error: 25.3 ± 1.2) compared with asymptomatic controls (28.5 ± 1.4). Cycle threshold values were significantly different across age 
groups, norovirus genogroups, timing of specimen collection, outbreak settings, and transmission modes. Genogroup II (GII) Ct 
values were associated with presence of symptoms (OR = 1.1), allowing us to estimate that 16% of diarrheal disease was attributable 
to norovirus. The optimized Ct cutoff led to poor sensitivity and specificity for genogroup I and GII.
Conclusions. Cycle threshold values were associated with host, pathogen, and outbreak factors. Cycle threshold values may not 
effectively distinguish disease-causing infection for individual patients, but they are useful for epidemiological studies aiming to 
attribute disease.
Keywords. attributable fractions; cycle threshold; norovirus; real-time PCR; receiver-operating characteristic analysis.
 
Norovirus affects people from all age groups and is associated 
with approximately one fifth of acute gastroenteritis (AGE) 
cases worldwide [1]. The World Health Organization esti-
mated that norovirus caused 684 million diarrheal illnesses and 
212 000 deaths in 2010 [2]. Reverse-transcriptase polymerase 
chain reaction (RT-PCR) assays are the most commonly used 
diagnostic methods for surveillance, outbreak investigations, 
and research, and this has allowed for more robust estimates 
of the norovirus disease burden [3]. RT-PCR assays can detect 
norovirus at low levels in stool specimens (ie, high “analytical” 
sensitivity and specificity), and, because the virus can be shed 
for a prolonged period of time, the virus can be detected in 
samples from asymptomatic individuals. Using RT-PCR, noro-
virus can be detected in 7% of individuals without AGE symp-
toms compared with 18% with symptoms [1]. Hence, detection 
of virus does not necessarily indicate that norovirus was a 
cause of disease, and the “clinical” sensitivity and specificity of 
RT-PCR assays (ie, identification of disease-causing etiology) 
are debatable.
The cycle threshold (Ct) value of real-time RT-PCR assays, 
which is the number of PCR cycles required for the fluores-
cent signal to cross the threshold, has been used to determine 
disease etiology for some pathogens [4–6]. The Ct value is 
inversely proportional to the amount of viral nucleic acid in 
specimens (ie, lower Ct values indicate higher amount of virus), 
so it can be used as a proxy of viral load. For rotavirus A, symp-
tomatic cases have significantly higher viral loads than asymp-
tomatic controls, and the optimal Ct value cutoff can be selected 
to distinguish disease-causing infection [5, 6]. For norovirus, 
in contrast, studies showed the same/similar concentrations or 
detection rates between symptomatic cases and asymptomatic 
controls [7–9]. Even if there was a significant difference in nor-
ovirus viral load between cases and controls, the distribution 
of viral load substantially overlapped [10–12]. Because of these 
issues, it is not clear whether higher concentrations of norovirus 
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represent symptomatic infection nor whether the norovirus Ct 
value should be considered for clinical diagnostic purposes.
In addition to individual clinical diagnoses, some studies 
have attempted to use Ct values to estimate attributable fraction 
(AF) of norovirus-related illness [13, 14]. However, it has been 
poorly understood how Ct values vary across host and patho-
gen characteristics and outbreak and logistical factors, which 
could affect these attribution analyses.
To fill these gaps, we assessed how norovirus Ct values of 
human clinical specimens are associated with the presence of 
symptoms as well as demographic and outbreak characteris-
tics. We also attempted to quantify an optimal cutoff for the Ct 
value to differentiate symptomatic from asymptomatic norovirus 
infections.
METHODS
Study Sources
We extracted laboratory and epidemiological data from 3 
study sources (Supplementary Table 1). The first study source 
included data from norovirus outbreaks collected through 
CaliciNet, a national norovirus outbreak surveillance network 
of public health laboratories in the Unites States coordinated by 
the Centers for Disease Control and Prevention [15]. Outbreak 
specimens are tested by real-time RT-PCR for norovirus by 
CaliciNet certified laboratories. Positive specimens are gen-
otyped by sequencing [16]. CaliciNet laboratories do not test 
specimens from asymptomatic controls.
The second study source constitutes data from 2 popula-
tion-based studies conducted in Latin America. Becker-Dreps 
et al [17] tested stool specimens from sporadic diarrhea patients 
<5  years of age in randomly selected households in Nicaragua. 
They also collected stool specimens from healthy controls who 
were matched by sex, age group, and neighborhood with the diar-
rhea cases. In Ecuador, Lopman et al [18] conducted a birth cohort 
study to estimate the incidence of norovirus gastroenteritis. They 
enrolled healthy children <2 weeks of age, and they routinely col-
lected stool specimens from all children from birth to 3 years.
The third study source includes data from routine surveil-
lance of AGE and healthy controls enrolled through the New 
Vaccine Surveillance Network (NVSN) from 2008 to 2012. 
Active, prospective surveillance methods have been previously 
published [19] and include enrollment of children <11  years 
of age having diarrhea and/or vomiting and seen in a hospi-
tal, emergency department, or outpatient clinic in 1 of 7 large 
medical institutions throughout the United States. Healthy con-
trols had no diarrhea or vomiting in the 2 weeks preceding their 
enrollment at well child visits at these medical institutions.
Norovirus Real-Time Reverse-Transcriptase Polymearse Chain Reaction 
and Genotyping
All studies used the same norovirus real-time RT-PCR protocol 
as described previously [15, 17–19]. Positive samples were then 
genotyped by Sanger sequencing using conventional RT-PCR 
products, and sequences were genotyped by comparing them 
with norovirus reference sequences [15].
Rotavirus Testing Methods
Stool samples were tested for rotavirus by RT-PCR or by a com-
mercial enzyme immunoassay (Rotaclone; Meridian Bioscience 
or Oxoid, Cambridge, United Kingdom) in the Latin America 
studies and NVSN [17, 19].
Assessing Associations With Cycle Threshold Values
We built Poisson regression models to assess relationships 
between norovirus Ct values and demographic, clinical, and 
outbreak characteristics. We fit multivariate models to con-
trol for potential confounders, because it has been known that 
demographic, clinical, and outbreak characteristics are closely 
related to each other. For example, many of the elderly, espe-
cially women, live in long-term-care facilities where norovirus 
outbreaks frequently occur [20], and specimens may be col-
lected earlier in these settings.
A total of 4 models were built for different objectives as 
described in Table 1. In the first model (Model 1), we included 
sex, age, presence of AGE symptoms, month of symptom onset, 
and norovirus genotype as independent variables. Because the 
date of symptom onset was unavailable for the symptomatic 
cases in the Ecuador dataset, month of specimen collection was 
used as a proxy of month of illness onset. For asymptomatic con-
trols, month of specimen collection was used to indicate timing. 
Model 1 was fit with each of the 3 studies separately. In addition, 
it was fit with a combined dataset of these 3 studies including a 
“study” as a random effect and other factors as fixed effects. The 
second model (Model 2) was created by adding the timing of 
specimen collection (ie, days between symptom onset and spec-
imen collection) to Model 1 to evaluate its relationship with nor-
ovirus Ct values. Because asymptomatic controls did not have 
symptom onset, Model 2 was fit only with symptomatic cases 
in each study source as well as in the combined dataset, and the 
presence of AGE symptoms was removed from the model. The 
third model (Model 3) was created by adding outbreak charac-
teristics (ie, transmission mode and outbreak setting) to Model 
2 to assess how they are associated with norovirus Ct values. 
We fit Model 3 with outbreak data collected through CaliciNet. 
Lastly, the fourth model (Model 4) was built by adding rotavirus 
testing results to Model 1 to evaluate whether coinfection with 
rotavirus was associated with norovirus Ct values. Model 4 was 
fit with the Latin America studies and NVSN as well as a com-
bined dataset of these 2. CaliciNet was not included in Model 4 
because rotavirus testing results were not available. With these 4 
models, we calculated adjusted means of norovirus Ct values in 
each subgroup using the pseudo-likelihood technique. We also 
performed all-possible pairwise comparisons of adjusted means 
using Tukey’s method, which correct for multiple testing [21].
When fitting these models, we could not include some records 
because of their missing information on variables. Most importantly, 
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50% of the records in the CaliciNet data were not used in the mod-
els, mainly because of missing date of symptom onset (see Results). 
To see whether the missing data had any significant effects, we ran 
Model 1 with datasets created by multiple imputation and found 
that none of the estimates appreciably changed after imputation. 
Therefore, we used the models with only complete data. All analyses 
were performed with SAS 9.3 (SAS Institute, Cary, NC).
Association With Norovirus Disease and Attributable Fraction
We estimated odds ratios (ORs) from multivariate logistic 
regression models, where the outcome was case-control status 
and the predictor was an inverse measure of norovirus Ct value 
(Cq), which was calculated as follows: Cq Ct value= -41 . For 
this analysis, Ct values for negative specimens (ie, specimens 
whose fluorescent signals did not cross the threshold by the 
last PCR cycle) were set to be 41 and their Cq values were set 
to be 0. To control for potential confounders, we included the 
detection of norovirus (positive vs negative), patients’ age, sex, 
and month of symptom onset in the model. Due to the sparse 
data, we removed variables by backward elimination (α = 0.05) 
and fit the model separately with each study. To attribute the 
proportion of AGE cases to norovirus in each study, we also 
calculated population AFs by summing attributions of norovi-
rus-related illness across each of the Cq values. 
AF AF Cq
ORi i i i
å = -, ( | ) * ( )where casesPr 1 1
where Pr( | )Cq casesi  is the proportion of i
th Cq value among 
symptomatic cases. Confidence intervals (CIs) were estimated 
by bootstrap with 1000 iterations. The models were run sep-
arately for genogroup I  (GI) and genogroup II (GII). The 
CaliciNet data were not included in these analyses, because all 
its data are from symptomatic subjects.
Receiver-Operating Characteristic Analysis
We performed receiver-operating characteristic (ROC) analy-
sis with the aim of defining an optimal Ct cutoff to distinguish 
symptomatic norovirus infections and asymptomatic infections. 
We defined a reference positive group and reference negative 
group based on the presence of AGE symptoms and timing of 
specimen collection. Reference positive included specimens 
collected from symptomatic cases within 3  days of symptom 
onset. Reference negative included specimens collected from 
asymptomatic controls regardless of the timing of specimen 
collection. All specimens, including reference negatives, were 
positive for norovirus by real-time RT-PCR and confirmed by 
sequencing. We conducted ROC analyses separately for noro-
virus GI and GII. The Youden index (sensitivity+specificity-1) 
was used to identify an optimal cutoff for the Ct value [22–24].
RESULTS
Our dataset included 12 875 clinical specimens from CaliciNet, 
659 from the Latin America studies, and 3997 from NVSN. 
Of these, norovirus Ct values were reported for 12 039 (94%) 
in CaliciNet, 227 (34%) in the Latin America studies, and 644 
(16%) in NVSN. The remaining was norovirus negative by real-
time RT-PCR. Median age was 77 years in CaliciNet, 2 years in 
Table 1. Objectives and Variables, Study Sources, and Subjects Included in Four Multivariate Poisson Regression Models
Model Characteristics Model 1 Model 2 Model 3 Model 4
Objectives To assess how host and virus 
factors may affect norovirus 
Ct values
To assess how the timing of 
specimen collection may 
affect norovirus Ct values 
among symptomatic cases
To assess how outbreak charac-
teristics may affect norovirus 
Ct values
To assess how rotavirus coin-
fection may affect norovirus 
Ct values
Variables
 Sex ✓ ✓ ✓ ✓
 Age ✓ ✓ ✓ ✓
 Presence of AGE symptoms ✓ ✓
 Month of symptom onset ✓ ✓ ✓ ✓
 Norovirus genotype (or 
genogroup)
✓ ✓ ✓ ✓
 Days between symptom 
onset and specimen 
collection
✓ ✓
 Transmission modes ✓
 Outbreak setting ✓
 Rotavirus testing result ✓
Study sources
 CaliciNet ✓ ✓ ✓
 Latin America studies ✓ ✓ ✓
 NVSN ✓ ✓ ✓
Subjects Both symptomatic cases and 
asymptomatic controls
Symptomatic cases only Symptomatic cases only Both symptomatic cases and 
asymptomatic controls
Abbreviations: AGE, acute gastroenteritis; Ct, cycle threshold; NVSN, New Vaccine Surveillance Network. 
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the Latin America studies, and 1 year in NVSN. Norovirus GI 
Ct values were lowest (median, 24; range, 6–43) in CaliciNet, 
followed by NVSN (median, 27; range, 16–40) and the Latin 
America studies (median, 29; range, 19–38) (Figure  1). For 
GII, CaliciNet (median, 22; range, 6–43) and NVSN (median, 
22; range, 10–39) had lower Ct values compared with the Latin 
America studies (median, 28; range, 16–38). Lower Ct values 
were observed among symptomatic cases (GI: median 24, range 
6–43; GII: median 22, range 6–43) compared with asympto-
matic controls (GI: median 28, range 19–40; GII: median 28, 
range 15–38), but the distributions of Ct values substantially 
overlapped between the 2 groups (Figure 1).
Of 12 910 norovirus-positive specimens, Model 1 included 
5989 (50%) from CaliciNet, 194 (85%) from the Latin America 
studies, and 585 (91%) from NVSN. The remaining records 
were not used in Model 1, because both norovirus GI and GII 
were detected by RT-PCR from the same specimens (n = 40), 
because of the missing information on the factors included in 
Model 1 (n = 6086), or both (n = 16).
After controlling for other covariates, a number of factors were 
found to have significant associations with norovirus Ct val-
ues. In Model 1 (Table 2), norovirus Ct values were significantly 
lower among symptomatic cases (model-adjusted mean ± stand-
ard error: 25.3  ±  1.2) than asymptomatic controls (28.5  ±  1.4, 
P < .0001) (Figure 2A). Lower Ct values were found in specimens 
from young children and the elderly compared with the middle 
age group (P  <  .0001) (Figure  2C). We also found a significant 
association between the month of illness onset and Ct value in the 
combined dataset (P = .03), but the difference was relatively small 
and not significant in the individual study sources (Supplementary 
Figure 1C and Supplementary Table 2). Variation in Ct values was 
observed across norovirus genotypes (P < .0001) (Supplementary 
Figure 1D); overall, specimens positive for norovirus GII had lower 
Ct values (26.2 ± 1.1) than specimens positive for GI (27.4 ± 1.1, 
P < .0001) (Figure 2B). We did not find any evidence of an asso-
ciation of patients’ sex with Ct values (Supplementary Figure 1A).
In Model 2 with symptomatic cases, the Ct values were sig-
nificantly higher when specimens were collected >7 days after 
illness onset (range, 26.4−27.5), compared with those collected 
within 7 days (range, 24.5−25.0; P < .0001) (Table 3 and Figure 
2D). In Model 3, specimens from outbreaks involving trans-
mission by food or unknown/other modes had significantly 
lower Ct values (22.6 ± 0.7 and 22.8 ± 0.7, respectively) than 
those having person-to-person transmission (23.3 ± 0.6, Tukey-
adjusted P < .05). Among all the different outbreak settings, 
specimens from cruise ship outbreaks had the lowest Ct values 
(20.8 ± 0.9). Healthcare facilities had lower Ct values (23.0 ± 
0.9) than child care facilities (25.0 ± 1.0) and schools (24.5 ± 
0.9, Tukey-adjusted P < .05). According to Model 4, coinfection 
with rotavirus was not significantly associated with the norovi-
rus Ct value (Supplementary Figure 1B).
Norovirus GII Cq value was associated with presence of 
disease symptoms (OR = 1.13 (95% CI, 1.05–1.21) in Latin 
America and OR = 1.13 (95% CI, 1.08–1.18) in NVSN, Table 4 
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Figure 1. Distribution of norovirus Ct value by Study and by the presence of AGE symptoms. *Specimens infected with both GI and GII and specimens in which norovirus 
infection was not confirmed by sequencing are not included in these graphs. Abbreviations: AGE, acute gastroenteritis; NVSN, New Vaccine Surveillance Network; Ct value, 
cycle threshold value.
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and Supplementary Figure 2), but GI Cq was not (OR = 1.01 
(95% CI, 0.91–1.13) in Latin America and OR = 1.07 (95% CI, 
0.95–1.21) in NVSN). Based on this relationship, 16.0% and 
16.2% of diarrheal disease in the Latin America studies and 
NVSN, respectively, could be attributed norovirus GII.
According to the ROC analysis, the optimal Ct value cutoff 
with the highest Youden index was 26 for GI and 25 for GII 
(Figure 3 and Supplementary Table 3), but both sensitivity (GI, 
73%; GII, 76%) and specificity (GI, 65%; GII, 68%) were poor.
DISCUSSION
We found that host (AGE symptoms and age), pathogen (nor-
ovirus genotype), outbreak (transmission mode and setting), 
and logistical (timing of specimen collection) factors were 
significantly associated with norovirus real-time RT-PCR Ct 
values. The estimated mean Ct value was lower among symp-
tomatic cases than controls, after controlling for other factors 
in the Poisson regression models. However, the distributions 
overlapped between the symptomatic and asymptomatic indi-
viduals, and, therefore, there was no clear Ct value cutoff that 
differentiates symptomatic and asymptomatic infections with 
high clinical sensitivity and specificity.
We found higher Cq to be associated with disease symp-
toms. Using the model coefficients, we were able to estimate 
the fraction of diarrhea that can be attributed to norovirus. As 
expected, these fractions (16.0% in the Latin America studies 
and 16.2% in NVSN) were lower than the prevalence of noro-
virus (20.8% in the Latin America studies and 19.2% in NVS). 
Studies without healthy controls may be able to apply our esti-
mated ORs to their Ct value data and calculate AFs of norovirus 
for their study.
Not only the presence of symptoms but also other factors 
were found to have significant associations with norovirus Ct 
values. Young children and the elderly had higher viral load 
than those from the middle age group potentially as a result 
of lack of prior exposures to norovirus among young children 
or immune senescence of the elderly. Most of the people in 
the middle age group, in contrast, might have some degree of 
acquired immunity against norovirus from previous exposure. 
The relationship between the timing of specimen collection and 
Ct value highlights the importance of early specimen collection 
for diagnostic purposes. The Ct values were significantly lower 
in specimens that were collected within 7 days after the symp-
toms onset. This confirms the recommendations to collect stool 
samples as early as possible after onset of symptoms preferably 
within 1 week [25]. We found that GII-positive specimens had 
slightly lower Ct values compared with GI-positive samples, but 
overall Ct values varied across different genotypes even among 
viruses belonging to the same genogroups. This may be due to 
real differences between genotypes but more likely is caused by 
the difference in sensitivity of the PCR assays for the different 
genotypes, suggesting that the Ct values need to be interpreted 
Table  2. Mean Ct Values Estimated by the Multivariate Mixed-Effect 
Poisson Regression Model (Model 1)
Characteristics
Number of 
Specimens Mean Estimate  (95% CI) P Value
 Sex .06
 Male 2548 26.7 (24.4–29.3)
 Female 4220 27.0 (24.6–29.6)
Age group <.0001
 <1 yr 260 25.8 (23.5–28.4)
 1 to <2 yr 340 26.2 (23.8–28.7)
 2 to <3 yr 174 26.7 (24.3–29.3)
 3 to <4 yr 89 26.6 (24.1–29.4)
 4 to <5 yr 36 28.7 (25.7–32.1)
 5 to <10 yr 148 27.9 (25.3–30.8)
 10 to <18 yr 149 28.1 (25.5–31.1)
 18 to <45 yr 837 28.1 (25.5–30.9)
 45 to <65 yr 907 27.0 (24.5–29.7)
 65 to <75 yr 573 26.5 (24.1–29.2)
 75 to <85 yr 1114 25.9 (23.5–28.5)
 85 to <95 yr 1814 26.0 (23.6–28.5)
 ≥95 yr 327 26.0 (23.6–28.7)
Cases vs controls <.0001
 Controls 173 28.5 (25.9–31.4)
 Cases 6595 25.3 (23.1–27.8)
Month of onset .03
 January 1274 26.7 (24.3–29.3)
 February 1192 26.6 (24.2–29.1)
 March 1076 26.9 (24.5–29.5)
 April 597 26.6 (24.2–29.2)
 May 414 27.5 (25.0–30.2)
 June 235 26.6 (24.2–29.3)
 July 196 27.3 (24.8–30.1)
 August 120 26.6 (24.2–29.4)
 September 159 26.7 (24.3–29.5)
 October 218 27.8 (25.3–30.7)
 November 457 26.3 (24.0–28.9)
 December 830 26.7 (24.3–29.3)
Norovirus genotype <.0001
 GI.1 11 30.9 (26.8–35.6)
 GI.2 81 26.3 (23.9–29.0)
 GI.3 371 25.6 (23.4–28.0)
 GI.4 67 28.8 (26.1–31.9)
 GI.5 45 30.5 (27.4–33.8)
 GI.6 247 30.0 (27.4–32.8)
 GI.7 39 23.3 (20.9–26.1)
 GI.8 8 28.9 (24.6–33.9)
 GI.9 4 33.6 (27.4–41.3)
GI untypeable 1 24.1 (15.4–37.8)
 GII.1 331 28.4 (26.0–31.1)
 GII.2 133 26.1 (23.7–28.6)
 GII.3 84 26.2 (23.7–28.9)
 GII.4_DenHaag 352 26.3 (24.0–28.8)
 GII.4_NewOrleans 1825 26.6 (24.3–29.0)
 GII.4_Osaka 14 27.6 (24.0–31.7)
 GII.4_Sydney 2256 25.8 (23.6–28.2)
 GII.4_Yerseke 2 23.0 (16.9–31.4)
 GII.4_Untypeable 10 27.9 (23.9–32.6)
 GII.5 27 28.6 (25.5–32.2)
 GII.6 382 24.9 (22.8–27.3)
 GII.7 167 24.3 (22.1–26.6)
 GII.8 3 24.6 (18.9–32.1)
 GII.12 108 28.7 (26.1–31.6)
 GII.13 75 24.0 (21.8–26.6)
 GII.14 34 23.9 (21.4–26.7)
 GII.15 1 18.3 (11.1–30.2)
 GII.16 2 25.5 (18.6–34.8)
 GII.17 26 24.9 (22.1–28.1)
 GII.21 2 35.4 (27.1–46.2)
 GII.23 6 30.0 (25.4–35.5)
 Unable to confirm 54 33.4 (30.3–36.9)
Abbreviations: CI, confidence interval; Ct, cycle threshold; GI, genogroup I; GII, genogroup II.
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carefully. Another explanation could be that the Ct differences 
can be attributed to differences in genetic susceptibility against 
the different genotypes [26, 27].
Significant relationships were also found between the out-
break characteristics and Ct values. Samples from cruise ship 
norovirus outbreaks had the lowest Ct value among all out-
break settings even after controlling for age and the timing of 
specimen collection. We cannot see a biological basis for lower 
Ct values in this setting, so we suspect that other unmeasured 
issues with specimen collection and storage quality may be 
residually cofounding this association. In addition, foodborne 
outbreaks were found to have lower Ct values compared with 
person-to-person outbreaks. A  potential hypothesis of this 
finding is that individuals are exposed to higher dose of viruses 
in foodborne outbreaks compared with person-to-person out-
breaks. However, even if exposure doses are higher, a human 
Table  3. Mean Ct Values Estimated by the Multivariate Mixed-Effect 
Poisson Regression Model by Timing of Specimen Collection, Outbreak 
Characteristics, and Rotavirus Coinfection (Model 2–4)
Characteristics
Number of 
Specimens
Mean 
Estimate  (95% CI) P Value
Specimen collection (Model 2) <.0001
 Before symptom onset 2 30.1 (22.3–40.5)
 Date of symptom onset 2270 24.9 (21.9–28.4)
 1–3 days after symptom 
onset
2738 24.5 (21.4–27.9)
 4–7 days after symptom 
onset
1184 25.0 (21.9–28.5)
 8–14 days after symptom 
onset
283 27.3 (23.9–31.2)
 15–30 days after symptom 
onset
38 27.5 (23.7–31.8)
 >30 days after symptom 
onset
12 26.4 (22.1–31.5)
Transmission mode (Model 3) .002
 Environmental 8 26.3 (22.6–30.5)
 Foodborne 852 22.6 (21.3–24.0)
 Person-to-person 3966 23.3 (22.0–24.7)
 Waterborne 13 23.0 (20.3–26.1)
 Unknown/other modes 1150 22.8 (21.5–24.1)
Outbreak setting (Model 3) <.0001
 Child care facility 93 25.0 (23.1–27.0)
 Correctional facility 83 23.1 (21.3–25.1)
 Cruise ships 76 20.8 (19.1–22.7)
 Food facility 607 24.0 (22.4–25.7)
 Healthcare facility 215 23.0 (21.3–24.7)
 Long-term care facility 3862 23.5 (21.9–25.2)
 School 347 24.5 (22.8–26.2)
 Other setting 670 23.7 (22.1–25.3)
 Unknown setting 36 24.8 (22.5–27.3)
Rotavirus (Model 4) .3
 Positive 54 29.2 (26.4–32.4)
 Negative 719 28.3 (25.9–30.9)
Abbreviations: CI, confidence interval; Ct, cycle threshold. 
Table  4. Association Between the Pathogen Quantity and Presence of 
Symptoms and Attributable Fractionsa
Norovirus 
Genogroup 
and Study
Odds Ratios per 1-Unit Increase in 
Cq Value (95% CI; P Value) Attributable Fractions
Norovirus GI
 Latin 
America
1.01 (0.91–1.13; P = .8) 1.1%
 NVSN 1.07 (0.95–1.21; P = .3) 0.9%
Norovirus GII
 Latin 
America
1.13 (1.05–1.21; P = .001) 16.0%
 NVSN 1.13 (1.08–1.18; P < .0001) 16.2%
Abbreviations: CI, confidence interval; Cq, inverse measure of norovirus Ct value which 
was calculated as Cq Ct value= -41 ; Ct, cycle threshold; GI, genogroup I; GII, genogroup 
II; NVSN, New Vaccine Surveillance Network.
aAll models except GI in the Latin America studies controlled for the detection of norovi-
rus (positive vs negative), patients’ age, sex, and month of symptom onset. The model for 
GI in the Latin America studies included the detection of norovirus and month of symp-
tom onset after backward elimination.
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Figure 3. Receiver-operating characteristic plots for norovirus genogroup I and genogroup II. Abbreviations: GI, genogroup I; GII, genogroup II.
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challenge study is not supportive of an association between 
inoculum dose and viral shedding [28]. Therefore, these find-
ings might be attributable to other unadjusted factors, such as 
investigation methods (eg, more intense investigations might 
be implemented for foodborne outbreaks). Further studies are 
needed to confirm these hypotheses.
An important limitation of our study is that comparing data 
generated in different laboratories (eg, 32 different CaliciNet lab-
oratories are currently certified) may have affected the Ct data. 
To address this issue, all staff completed standardized training 
to become certified to perform the norovirus assays, and labo-
ratories are biennially validated by having them complete a pro-
ficiency panel. In addition, mixed-effect models have accounted 
for correlation among specimens tested in each study. However, 
these approaches do not perfectly solve the issue. Another limi-
tation is that we could not assess a relationship between Ct val-
ues and clinical severity due to the lack of detailed clinical data. 
A strength of our study is the large sample size, which allowed us 
to include a number of variables into the models in an attempt 
to identify the independent effects of host, pathogen, outbreak, 
and logistical factors. As a result, we found that each of these 
factors was independently associated with norovirus Ct values 
after adjustment. The large sample size also helped us identify 
subtle differences in the Ct value across subgroups, which could 
have been missed if we had smaller populations.
CONCLUSIONS
In conclusion, we found that the Ct values were associated with 
presence of symptoms as well as various host, pathogen, out-
break, and logistical factors. The difference in Ct values was 
subtle and did not lend itself to discriminatory cutoff values for 
clinical diagnosis of individual specimens; however, those char-
acteristics associated with Ct values could be taken into account 
for evaluating disease burden or incidence of norovirus.
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